AU2021312894B2 - Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound - Google Patents
Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compoundInfo
- Publication number
- AU2021312894B2 AU2021312894B2 AU2021312894A AU2021312894A AU2021312894B2 AU 2021312894 B2 AU2021312894 B2 AU 2021312894B2 AU 2021312894 A AU2021312894 A AU 2021312894A AU 2021312894 A AU2021312894 A AU 2021312894A AU 2021312894 B2 AU2021312894 B2 AU 2021312894B2
- Authority
- AU
- Australia
- Prior art keywords
- day
- compound
- dose
- formula
- total
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055362P | 2020-07-23 | 2020-07-23 | |
| US63/055,362 | 2020-07-23 | ||
| PCT/US2021/042877 WO2022020663A1 (en) | 2020-07-23 | 2021-07-23 | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021312894A1 AU2021312894A1 (en) | 2023-02-23 |
| AU2021312894B2 true AU2021312894B2 (en) | 2025-09-11 |
Family
ID=77338898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021312894A Active AU2021312894B2 (en) | 2020-07-23 | 2021-07-23 | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound |
Country Status (21)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3243602A1 (en) | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018140299A1 (en) * | 2017-01-27 | 2018-08-02 | Eli Lilly And Company | N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107735190B (zh) * | 2016-07-22 | 2019-11-26 | 深圳市大富科技股份有限公司 | Usb金属管件加工设备及其上模板 |
| EP3829634A1 (en) * | 2018-07-31 | 2021-06-09 | Eli Lilly and Company | Combination therapy |
-
2021
- 2021-07-21 TW TW110126729A patent/TW202220650A/zh unknown
- 2021-07-21 AR ARP210102050A patent/AR123031A1/es unknown
- 2021-07-23 EP EP21755253.8A patent/EP4185291B1/en active Active
- 2021-07-23 CA CA3186808A patent/CA3186808A1/en active Pending
- 2021-07-23 IL IL300023A patent/IL300023A/en unknown
- 2021-07-23 JP JP2023504346A patent/JP2023535034A/ja active Pending
- 2021-07-23 CN CN202180063288.5A patent/CN116323604A/zh active Pending
- 2021-07-23 KR KR1020237005839A patent/KR20230043905A/ko not_active Withdrawn
- 2021-07-23 US US18/005,245 patent/US20230338349A1/en active Pending
- 2021-07-23 ES ES21755253T patent/ES3039536T3/es active Active
- 2021-07-23 WO PCT/US2021/042877 patent/WO2022020663A1/en not_active Ceased
- 2021-07-23 BR BR112023000975A patent/BR112023000975A2/pt unknown
- 2021-07-23 MX MX2023000993A patent/MX2023000993A/es unknown
- 2021-07-23 PH PH1/2023/550177A patent/PH12023550177A1/en unknown
- 2021-07-23 AU AU2021312894A patent/AU2021312894B2/en active Active
- 2021-07-23 PE PE2023000107A patent/PE20231031A1/es unknown
-
2023
- 2023-01-19 CL CL2023000194A patent/CL2023000194A1/es unknown
- 2023-01-19 CO CONC2023/0000594A patent/CO2023000594A2/es unknown
- 2023-01-20 DO DO2023000009A patent/DOP2023000009A/es unknown
- 2023-01-23 EC ECSENADI20235057A patent/ECSP23005057A/es unknown
- 2023-01-23 JO JOJO/P/2023/0018A patent/JOP20230018A1/ar unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018140299A1 (en) * | 2017-01-27 | 2018-08-02 | Eli Lilly And Company | N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023000194A1 (es) | 2023-07-21 |
| EP4185291C0 (en) | 2025-07-09 |
| CA3186808A1 (en) | 2022-01-27 |
| PE20231031A1 (es) | 2023-07-10 |
| IL300023A (en) | 2023-03-01 |
| BR112023000975A2 (pt) | 2023-02-07 |
| KR20230043905A (ko) | 2023-03-31 |
| CN116323604A (zh) | 2023-06-23 |
| ES3039536T3 (en) | 2025-10-22 |
| ECSP23005057A (es) | 2023-02-28 |
| AR123031A1 (es) | 2022-10-26 |
| MX2023000993A (es) | 2023-03-01 |
| PH12023550177A1 (en) | 2024-03-18 |
| AU2021312894A1 (en) | 2023-02-23 |
| EP4185291A1 (en) | 2023-05-31 |
| US20230338349A1 (en) | 2023-10-26 |
| JOP20230018A1 (ar) | 2023-01-23 |
| DOP2023000009A (es) | 2023-02-15 |
| CO2023000594A2 (es) | 2023-01-26 |
| WO2022020663A1 (en) | 2022-01-27 |
| EP4185291B1 (en) | 2025-07-09 |
| JP2023535034A (ja) | 2023-08-15 |
| TW202220650A (zh) | 2022-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023219839B2 (en) | Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders | |
| AU2016219650B2 (en) | Compositions and methods for extended therapy with aminopyridines | |
| WO2003050129A1 (en) | Use of phosphonate nucleotide analogue for treating hepatitis b virus infections | |
| JP2022031479A (ja) | アルツハイマー病治療に関連するアミロイド関連画像異常の治療または予防方法 | |
| TW200815014A (en) | Method of improved diuresis in individuals with impaired renal function | |
| AU2018279834A1 (en) | Liquid dosage forms to treat cancer | |
| CN111973592A (zh) | 治疗肌萎缩侧索硬化和神经病的方法 | |
| Browne et al. | Bioavailability of ACC‐9653 (phenytoin prodrug) | |
| EP4185291B1 (en) | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound | |
| Barcia et al. | Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care | |
| WO2014210369A2 (en) | Reversal of cysteine-inactivated neuromuscular blocking drugs with combinations of reversal agents | |
| US5712282A (en) | Method for therapeutically treating tardive dyskinesia and uses thereof | |
| JP6454436B1 (ja) | ペマフィブラートを含有する医薬 | |
| US20240245666A1 (en) | Dosing regimens | |
| HK40084518A (en) | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound | |
| HK40084518B (en) | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound | |
| KRESS et al. | Pulmonary and meningeal cryptococcosis: Successful treatment of the meningitis with lateral cerebral intraventricular injection of amphotericin B | |
| JP2023049008A (ja) | 1回当たりの投与量がイサブコナゾール換算で100~400mgである、イサブコナゾール又はそのプロドラッグを有効成分として含有する製剤 | |
| Liau et al. | Efficacy and safety of barnidipine compared with felodipine in the treatment of hypertension in Chinese patients | |
| TW200418468A (en) | Liquid pharmaceutical formulations containing 3,7-diazabicyclo[3,3,1]nonane compounds and method of treatments relating to anti-arrhytmic events | |
| US20250222003A1 (en) | Pharmaceutical composition for treating solid tumors | |
| JP2018177773A (ja) | 医薬 | |
| Brown et al. | Phase I trial of sulofenur (LY186641) given orally on a daily× 21 schedule | |
| US20230201107A1 (en) | Compositions and methods of administering baclofen | |
| JP5992086B1 (ja) | 月経前不快気分障害及び/又は月経前症候群の予防、改善及び治療用医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |